EDN1 (Endothelin-1) variants and mutations
EDN1 (also known as Endothelin-1) is a human protein-coding gene encoding an endothelin-1 protein. It is processed to endothelin-1, a potent vasoconstrictor that regulates vascular tone, blood pressure, and vascular remodeling. Excess signaling contributes to pulmonary arterial hypertension and other cardiovascular diseases and is targeted by endothelin-receptor antagonists. This analysis covers 459 EDN1 variants and mutations. Of these, 89% have computational variant effect predictions. Disease context includes auriculocondylar syndrome, question mark ears, isolated, and colorectal cancer. Example EDN1 variants include D2H, D2Y, and D2N.
Variant analysis overview
- Gene: EDN1
- Protein: Endothelin-1
- UniProt accession: P05305
- Organism: Homo sapiens
- Variants analyzed: 459
- Variant scope: all variants
- Completed: 2026-08-22
Variant and mutation evidence
- Variant composition: 263 unspecified-consequence records; 100 missense variants; 81 synonymous variants; 7 frameshift variants; 3 stop-gained variants; 4 splice-region variants; 1 in-frame deletions; 2 substitution
- Prediction scores: 408 variants have prediction scores (89% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: auriculocondylar syndrome, question mark ears, isolated, colorectal cancer, alcohol drinking, urinary tract obstruction, Varicose veins, hereditary disease, dementia, aortic valve stenosis, lymphatic system disorder, vein disorder, atrial fibrillation.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable EDN1 variants
Examples include D2H, D2Y, D2N, Y3C, L4W, L4L, L4F, L5P. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- D2H (p.Asp2His), ExAC rs201943749, TOPMed rs201943749, gnomAD rs201943749, REVEL 0.53, MetaLR 0.72, Uncertain significance, Inborn genetic diseases
- D2Y (p.Asp2Tyr), ExAC rs201943749, TOPMed rs201943749, gnomAD rs201943749, REVEL 0.62, MetaLR 0.73
- D2N (p.Asp2Asn), gnomAD 6-12290633-G-A, REVEL 0.44, MetaLR 0.48
- Y3C (p.Tyr3Cys), gnomAD 6-12290637-A-G, REVEL 0.49, MetaLR 0.37
- L4W (p.Leu4Trp), NCI-TCGA Cosmic COSV6508, Variant assessed as somatic; moderate impact.
- L4L (p.Leu4Leu), gnomAD 6-12290641-G-A, CADD 10.40
- L4F (p.Leu4Phe), gnomAD 6-12290641-G-T, REVEL 0.17, MetaLR 0.05
- L5P (p.Leu5Pro), Ensembl rs1762651553
- L5F (p.Leu5Phe), gnomAD 6-12290642-C-T, REVEL 0.19, MetaLR 0.14
- L5L (p.Leu5Leu), gnomAD 6-12290644-C-G, CADD 11.40
- M6I (p.Met6Ile), Ensembl rs2113792619
- M6T (p.Met6Thr), gnomAD 6-12290646-T-C, REVEL 0.47, MetaLR 0.45
- I7I (p.Ile7Ile), rs1366689925, gnomAD 6-12290650-T-A, CADD 14.00
- F8L (p.Phe8Leu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- S9C (p.Ser9Cys), TOPMed rs1459410291, gnomAD rs1459410291, REVEL 0.43, MetaLR 0.44
- S9F (p.Ser9Phe), gnomAD 6-12290655-C-T, REVEL 0.21, MetaLR 0.27
- S9A (p.Ser9Ala), rs777308856, []
- L10L (p.Leu10Leu), gnomAD 6-12290659-G-C, CADD 12.70
- L11L (p.Leu11Leu), rs1390120105, gnomAD 6-12290660-C-T, CADD 14.50
- L11Q (p.Leu11Gln), gnomAD 6-12290661-T-A, REVEL 0.63, MetaLR 0.75
- F12L (p.Phe12Leu), gnomAD 6-12290663-T-C, REVEL 0.16, MetaLR 0.11
- V13V (p.Val13Val), rs1762652082, gnomAD 6-12290668-G-A, CADD 14.50
- A14P (p.Ala14Pro), gnomAD 6-12290669-G-C, REVEL 0.61, MetaLR 0.35
- A14A (p.Ala14Ala), rs1444035458, gnomAD 6-12290671-T-C, CADD 14.80
- C15F (p.Cys15Phe), ExAC rs73722760, gnomAD rs73722760, REVEL 0.17, MetaLR 0.04
- C15S (p.Cys15Ser), ExAC rs73722760, gnomAD rs73722760, REVEL 0.18, MetaLR 0.13
- C15W (p.Cys15Trp), ExAC rs751638434, gnomAD rs751638434, REVEL 0.23, MetaLR 0.18
- C15L (p.Cys15Leu), rs372164724, gnomAD 6-12290670-C-CT, CADD 25.20
- C15C (p.Cys15Cys), rs751638434, gnomAD 6-12290674-C-T, CADD 14.70
- Q16H (p.Gln16His), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- Q16K (p.Gln16Lys), rs377019316, ClinGen CA3638577, ClinVar RCV002718450, ESP rs377019316, REVEL 0.44, MetaLR 0.48, Uncertain significance, Inborn genetic diseases
- Q16L (p.Gln16Leu), ExAC rs750687688, gnomAD rs750687688
- Q16P (p.Gln16Pro), ExAC rs750687688, gnomAD rs750687688, REVEL 0.41, MetaLR 0.43
- Q16* (p.Gln16Ter), gnomAD 6-12290675-C-T, CADD 37.00
- G17* (p.Gly17Ter), ExAC rs780635071
- G17E (p.Gly17Glu), ExAC rs755489890, gnomAD rs755489890, REVEL 0.80, MetaLR 0.76
- G17R (p.Gly17Arg), ExAC rs780635071, REVEL 0.81, MetaLR 0.79
- A18G (p.Ala18Gly), ExAC rs746459355
- A18S (p.Ala18Ser), ExAC rs777308856, TOPMed rs777308856, gnomAD rs777308856, REVEL 0.32, MetaLR 0.36
- A18T (p.Ala18Thr), ExAC rs777308856, TOPMed rs777308856, gnomAD rs777308856, REVEL 0.24, MetaLR 0.35
- P19L (p.Pro19Leu), ExAC rs770493724, TOPMed rs770493724, gnomAD rs770493724, REVEL 0.22, MetaLR 0.31
- P19Q (p.Pro19Gln), ExAC rs770493724, TOPMed rs770493724, gnomAD rs770493724
- P19T (p.Pro19Thr), gnomAD 6-12290684-C-A, REVEL 0.21, MetaLR 0.26
- P19A (p.Pro19Ala), gnomAD 6-12290684-C-G, REVEL 0.22, MetaLR 0.19
- P19P (p.Pro19Pro), gnomAD 6-12290686-A-C, CADD 15.00
- E20D (p.Glu20Asp), gnomAD 6-12290689-A-C, REVEL 0.13, MetaLR 0.22
- T21K (p.Thr21Lys), Ensembl rs867359218, REVEL 0.50, MetaLR 0.59
- T21T (p.Thr21Thr), rs776204382, gnomAD 6-12290692-A-G, CADD 24.70
- A22E (p.Ala22Glu), 1000Genomes rs533813384, ExAC rs533813384, TOPMed rs533813384, gnomAD rs533813384, REVEL 0.61, MetaLR 0.31
- V23I (p.Val23Ile), TOPMed rs780775953, gnomAD rs780775953, REVEL 0.33, MetaLR 0.48
- V23A (p.Val23Ala), gnomAD 6-12292344-T-C, REVEL 0.11, MetaLR 0.20
- V23V (p.Val23Val), gnomAD 6-12292345-C-T, CADD 6.59
- G25V (p.Gly25Val), TOPMed rs1762704772
- G25G (p.Gly25Gly), rs1278863137, gnomAD 6-12292351-C-G, CADD 2.25
- A26S (p.Ala26Ser), TOPMed rs1367007262, gnomAD rs1367007262, REVEL 0.29, MetaLR 0.30
- A26T (p.Ala26Thr), rs1367007262, NCI-TCGA Cosmic COSV1010, TOPMed rs1367007262, gnomAD rs1367007262, REVEL 0.07, MetaLR 0.18, Uncertain significance, Inborn genetic diseases
- A26P (p.Ala26Pro), gnomAD 6-12292352-G-C, REVEL 0.35, MetaLR 0.53
- A26A (p.Ala26Ala), rs760951012, gnomAD 6-12292354-T-G, CADD 1.78
- E27D (p.Glu27Asp), TOPMed rs1762705280, REVEL 0.20, MetaLR 0.26
- E27K (p.Glu27Lys), 1000Genomes rs553767245, ExAC rs553767245, TOPMed rs553767245, gnomAD rs553767245, REVEL 0.43, MetaLR 0.38
- L28I (p.Leu28Ile), rs754109007, ExAC rs754109007, gnomAD rs754109007, REVEL 0.35, MetaLR 0.72, Variant assessed as somatic; moderate impact.
- L28R (p.Leu28Arg), gnomAD 6-12292359-T-G, REVEL 0.46, MetaLR 0.64
- S29N (p.Ser29Asn), Ensembl rs1762705494
- S29R (p.Ser29Arg), Ensembl rs1762705425, REVEL 0.39, MetaLR 0.48
- S29S (p.Ser29Ser), rs759759347, gnomAD 6-12292363-C-T, CADD 8.64
- A30E (p.Ala30Glu), rs202087445, ClinGen CA3638618, ClinVar RCV003177900, ESP rs202087445, REVEL 0.17, MetaLR 0.17, Uncertain significance, Inborn genetic diseases
- A30T (p.Ala30Thr), gnomAD rs1479572510, REVEL 0.17, MetaLR 0.03
- A30V (p.Ala30Val), rs202087445, ClinGen CA134217336, ClinVar RCV004384557, ClinVar RCV005392771, REVEL 0.13, MetaLR 0.17, Uncertain significance, Question mark ears, isolated; Auriculocondylar syndrome 3; Inborn genetic diseas
- A30A (p.Ala30Ala), rs150035515, gnomAD 6-12292366-G-A, CADD 0.53
- V31A (p.Val31Ala), Ensembl rs2113794812
- V31V (p.Val31Val), gnomAD 6-12292369-G-A, CADD 0.47
- G32S (p.Gly32Ser), ExAC rs749973432, gnomAD rs749973432, REVEL 0.15, MetaLR 0.13
- E33G (p.Glu33Gly), TOPMed rs1474510268, gnomAD rs1474510268, REVEL 0.28, MetaLR 0.23
- N34D (p.Asn34Asp), Ensembl rs2113794825
- N34K (p.Asn34Lys), gnomAD rs1263267835, REVEL 0.12, MetaLR 0.10
- N34N (p.Asn34Asn), gnomAD 6-12292378-C-T, CADD 0.72
- G35R (p.Gly35Arg), ExAC rs755650656, TOPMed rs755650656, gnomAD rs755650656, REVEL 0.14, MetaLR 0.23, Benign, not provided
- G35S (p.Gly35Ser), ExAC rs755650656, TOPMed rs755650656, gnomAD rs755650656, REVEL 0.15, MetaLR 0.17
- G35D (p.Gly35Asp), gnomAD 6-12292380-G-A, REVEL 0.26, CADD 8.70
- G35G (p.Gly35Gly), rs1189074850, gnomAD 6-12292381-C-T, CADD 3.83
- G36R (p.Gly36Arg), rs183694577, 1000Genomes rs183694577, ExAC rs183694577, TOPMed rs183694577, REVEL 0.25, MetaLR 0.31, Benign, not provided
- G36W (p.Gly36Trp), gnomAD 6-12292382-G-T, REVEL 0.27, CADD 24.10
- E37G (p.Glu37Gly), ExAC rs778827439, gnomAD rs778827439, REVEL 0.18, MetaLR 0.26
- K38E (p.Lys38Glu), ExAC rs748015875, gnomAD rs748015875
- K38N (p.Lys38Asn), Ensembl rs1581885356
- K38I (p.Lys38Ile), gnomAD 6-12292389-A-T, REVEL 0.35, CADD 7.02
- P39T (p.Pro39Thr), ExAC rs772178393, gnomAD rs772178393, REVEL 0.12, MetaLR 0.30
- T40A (p.Thr40Ala), TOPMed rs1490793727, REVEL 0.15, MetaLR 0.07
- T40I (p.Thr40Ile), 1000Genomes rs149399492, ESP rs149399492, ExAC rs149399492, TOPMed rs149399492, REVEL 0.17, MetaLR 0.24, Uncertain significance
- T40N (p.Thr40Asn), 1000Genomes rs149399492, ESP rs149399492, ExAC rs149399492, TOPMed rs149399492, REVEL 0.19, MetaLR 0.23, Uncertain significance, EDN1-related disorder
- T40S (p.Thr40Ser), 1000Genomes rs149399492, ESP rs149399492, ExAC rs149399492, TOPMed rs149399492, REVEL 0.22, MetaLR 0.10, Uncertain significance
- P41H (p.Pro41His), gnomAD rs1299418415, REVEL 0.40, MetaLR 0.71
- P41S (p.Pro41Ser), ESP rs144801601, TOPMed rs144801601
- P41P (p.Pro41Pro), rs367902098, gnomAD 6-12292399-C-G, CADD 6.18
- S42C (p.Ser42Cys), 1000Genomes rs576313237, ExAC rs576313237, gnomAD rs576313237, REVEL 0.32, MetaLR 0.41
- S42G (p.Ser42Gly), NCI-TCGA Cosmic COSV6508, Variant assessed as somatic; moderate impact.
- S42R (p.Ser42Arg), 1000Genomes rs576313237, ExAC rs576313237, gnomAD rs576313237, REVEL 0.38, MetaLR 0.26
- P43L (p.Pro43Leu), TOPMed rs1762707771
- P44L (p.Pro44Leu), TOPMed rs1193581265, REVEL 0.36, MetaLR 0.48
- P44S (p.Pro44Ser), ESP rs370873027, ExAC rs370873027, TOPMed rs370873027, gnomAD rs370873027, REVEL 0.18, MetaLR 0.27, Uncertain significance, Inborn genetic diseases
- W45C (p.Trp45Cys), Ensembl rs1762708175
- W45R (p.Trp45Arg), gnomAD rs1762708088, REVEL 0.27, MetaLR 0.32
- R46G (p.Arg46Gly), ESP rs200759992, ExAC rs200759992, TOPMed rs200759992, gnomAD rs200759992, REVEL 0.47, MetaLR 0.37
- R46L (p.Arg46Leu), rs1383893344, ClinGen CA362856288, ClinVar RCV002809558, TOPMed rs1383893344, REVEL 0.25, MetaLR 0.40, Uncertain significance, Inborn genetic diseases
- R46P (p.Arg46Pro), TOPMed rs1383893344, gnomAD rs1383893344, REVEL 0.32, MetaLR 0.43, Uncertain significance
- R46Q (p.Arg46Gln), TOPMed rs1383893344, gnomAD rs1383893344, REVEL 0.29, MetaLR 0.34, Uncertain significance, Inborn genetic diseases
- R46W (p.Arg46Trp), ESP rs200759992, ExAC rs200759992, TOPMed rs200759992, gnomAD rs200759992, REVEL 0.41, MetaLR 0.30, Uncertain significance, Inborn genetic diseases
- R46R (p.Arg46Arg), rs200759992, gnomAD 6-12292412-C-A, CADD 2.00
- L47V (p.Leu47Val), gnomAD 6-12292415-C-G, REVEL 0.14, CADD 13.90
- L47L (p.Leu47Leu), rs148565651, gnomAD 6-12292417-C-T, CADD 9.60
- R48C (p.Arg48Cys), rs1239711154, TOPMed rs1239711154, gnomAD rs1239711154, REVEL 0.49, MetaLR 0.75, Uncertain significance, Inborn genetic diseases
- R48H (p.Arg48His), ESP rs368802545, ExAC rs368802545, TOPMed rs368802545, gnomAD rs368802545, REVEL 0.33, MetaLR 0.37
- R48L (p.Arg48Leu), ESP rs368802545, ExAC rs368802545, TOPMed rs368802545, gnomAD rs368802545, REVEL 0.58, MetaLR 0.59
- R48G (p.Arg48Gly), gnomAD 6-12292418-C-G, REVEL 0.47, CADD 26.60
- R49P (p.Arg49Pro), gnomAD 6-12292419-G-GC, CADD 26.60
- R49Q (p.Arg49Gln), gnomAD 6-12292422-G-A, REVEL 0.87, CADD 32.00
- R49R (p.Arg49Arg), gnomAD 6-12292423-G-C, CADD 9.62
- S50F (p.Ser50Phe), ESP rs372723252, ExAC rs372723252, gnomAD rs372723252, REVEL 0.26, MetaLR 0.34
- S50P (p.Ser50Pro), TOPMed rs1762709122
- K51N (p.Lys51Asn), gnomAD 6-12292429-G-C, REVEL 0.74, CADD 26.20
- R52S (p.Arg52Ser), gnomAD 6-12292430-C-A, REVEL 0.81, CADD 28.50
- C53* (p.Cys53Ter), TOPMed rs1762709282
- S54P (p.Ser54Pro), gnomAD rs1284924294, REVEL 0.93, MetaLR 0.90
- S54S (p.Ser54Ser), rs1320555550, gnomAD 6-12292438-C-T, CADD 14.80
- S56* (p.Ser56Ter), gnomAD rs573471977
- S56W (p.Ser56Trp), gnomAD rs573471977, REVEL 0.56, MetaLR 0.81
- S56L (p.Ser56Leu), gnomAD 6-12292443-C-T, REVEL 0.49, CADD 27.40
- S56S (p.Ser56Ser), rs753421498, gnomAD 6-12292444-G-A, CADD 1.13
- S57T (p.Ser57Thr), gnomAD 6-12292445-T-A, REVEL 0.40, CADD 23.00
- S57F (p.Ser57Phe), gnomAD 6-12292446-C-T, REVEL 0.61, CADD 26.20
- S57S (p.Ser57Ser), gnomAD 6-12292447-C-A, CADD 11.20
- L58M (p.Leu58Met), ExAC rs754711482, gnomAD rs754711482, REVEL 0.36, MetaLR 0.54
- L58P (p.Leu58Pro), gnomAD 6-12292449-T-C, REVEL 0.82, CADD 30.00
- M59V (p.Met59Val), gnomAD 6-12292451-A-G, REVEL 0.39, CADD 22.60
- M59T (p.Met59Thr), gnomAD 6-12292452-T-C, REVEL 0.56, CADD 25.90
- M59I (p.Met59Ile), gnomAD 6-12292453-G-T, REVEL 0.43, CADD 28.10
- D60D (p.Asp60Asp), gnomAD 6-12292456-T-C, CADD 14.10
- K61E (p.Lys61Glu), gnomAD 6-12292457-A-G, REVEL 0.59, CADD 24.90
- K61N (p.Lys61Asn), gnomAD 6-12292459-A-C, REVEL 0.61, CADD 24.80
- E62Q (p.Glu62Gln), rs1561693994, ClinGen CA362856386, ClinVar RCV000723296, ClinVar RCV002535043, AlphaMissense 0.91, MetaLR 0.96, Uncertain significance, not provided
- E62K (p.Glu62Lys), gnomAD 6-12292456-T-TAA, CADD 32.00
- E62E (p.Glu62Glu), rs896673576, gnomAD 6-12292462-G-A, CADD 12.20
- C63R (p.Cys63Arg), Ensembl rs1762710045
- C63Y (p.Cys63Tyr), rs1064796796, ClinGen CA16618236, ClinVar RCV000483261, Ensembl rs1064796796, AlphaMissense 0.99, MetaLR 0.97, Uncertain significance, not provided
- V64D (p.Val64Asp), rs587777233, ClinGen CA150781, ClinVar RCV000106314, UniProt VAR 071152, AlphaMissense 0.98, MetaLR 0.84, Pathogenic, Question mark ears, isolated
- V64I (p.Val64Ile), gnomAD 6-12292466-G-A, REVEL 0.47, CADD 28.00
- Y65C (p.Tyr65Cys), NCI-TCGA Cosmic COSV6508, REVEL 0.97, MetaLR 0.89, Variant assessed as somatic; moderate impact.
- Y65L (p.Tyr65Leu), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- Y65Y (p.Tyr65Tyr), rs778544643, gnomAD 6-12292471-C-T, CADD 13.80
- F66V (p.Phe66Val), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- C67G (p.Cys67Gly), gnomAD 6-12292475-T-G, REVEL 0.98, CADD 32.00
- C67C (p.Cys67Cys), rs747917285, gnomAD 6-12292477-C-T, CADD 14.70
- L69L (p.Leu69Leu), rs758294039, gnomAD 6-12292481-C-T, CADD 13.70
- D70D (p.Asp70Asp), gnomAD 6-12292486-C-T, CADD 14.50
- I71V (p.Ile71Val), ExAC rs777792460, gnomAD rs777792460, REVEL 0.73, MetaLR 0.82
- I72M (p.Ile72Met), gnomAD 6-12292492-T-G, REVEL 0.81, CADD 24.20
- W73* (p.Trp73Ter), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- V74G (p.Val74Gly), NCI-TCGA Cosmic COSV1010, Variant assessed as somatic; moderate impact.
- V74V (p.Val74Val), gnomAD 6-12292498-C-T, CADD 14.30
- N75K (p.Asn75Lys), 1000Genomes rs565425223, ExAC rs565425223, gnomAD rs565425223, REVEL 0.85, MetaLR 0.87
- N75S (p.Asn75Ser), ExAC rs746943183, gnomAD rs746943183, REVEL 0.91, MetaLR 0.88
- N75Y (p.Asn75Tyr), TOPMed rs912386275, REVEL 0.97, MetaLR 0.88
- N75T (p.Asn75Thr), gnomAD 6-12292500-A-C, REVEL 0.90, CADD 29.90
- T76N (p.Thr76Asn), ExAC rs776827646, gnomAD rs776827646, REVEL 0.83, MetaLR 0.88
- P77H (p.Pro77His), rs587777232, ClinGen CA150780, ClinVar RCV000106313, UniProt VAR 071153, AlphaMissense 0.89, MetaLR 0.85, Pathogenic, Auriculocondylar syndrome 3
- P77P (p.Pro77Pro), rs755064642, gnomAD 6-12292507-C-T, CADD 13.00
- E78G (p.Glu78Gly), ExAC rs770093045, gnomAD rs770093045, REVEL 0.22, MetaLR 0.32, Uncertain significance, EDN1-related disorder
- E78Q (p.Glu78Gln), gnomAD rs1446318735
- E78K (p.Glu78Lys), gnomAD 6-12292508-G-A, REVEL 0.67, CADD 32.00
- E78E (p.Glu78Glu), gnomAD 6-12293941-G-A, CADD 18.80
- H79R (p.His79Arg), ESP rs144271441
- H79Y (p.His79Tyr), ExAC rs774749384, gnomAD rs774749384, REVEL 0.45, MetaLR 0.51
- H79Q (p.His79Gln), gnomAD 6-12293944-C-G, REVEL 0.27, CADD 23.40
- H79H (p.His79His), rs762278997, gnomAD 6-12293944-C-T, CADD 8.94
- V80D (p.Val80Asp), gnomAD rs1191532177, REVEL 0.58, MetaLR 0.34
- V80I (p.Val80Ile), rs147381256, ClinGen CA3638676, ClinVar RCV000935196, 1000Genomes rs147381256, REVEL 0.14, MetaLR 0.13, Likely benign, not provided
- P82L (p.Pro82Leu), ESP rs139407538, ExAC rs139407538, TOPMed rs139407538, gnomAD rs139407538, REVEL 0.74, MetaLR 0.83
- P82R (p.Pro82Arg), NCI-TCGA Cosmic COSV1010, Variant assessed as somatic; moderate impact.
- P82P (p.Pro82Pro), rs376892399, gnomAD 6-12293953-G-A, CADD 0.60
- Y83* (p.Tyr83Ter), rs587777234, ClinGen CA150782, ClinVar RCV000106315, Ensembl rs587777234, Pathogenic
Public EDN1 analysis runs
- EDN1 analysis run — EDN1 (459 variants) — completed 2026-08-22